Physician profile
Lisa Steinberg
NPI 1205311677
$4,454.59
in general payments reported to CMS, 2019-2025
53 companies · $16.39 in 2025
The $16.39 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.01 · 2022: $882 · 2023: $3,236 · 2024: $296 · 2025: $16.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.38 |
| Education | $340.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $384.78 | 2022-2025 | Kisqali, Piqray |
| Lilly USA, LLC | $346.37 | 2022-2023 | Retevmo, Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $296.43 | 2023 | Imfinzi, Calquence, Enhertu |
| Abbvie INC. | $252.08 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $225.32 | 2021-2023 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $209.13 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $182.19 | 2022-2023 | Ninlaro, Fruzaqla, Alunbrig |
| Astellas Pharma US INC | $178.46 | 2022-2023 | Xtandi, Padcev |
| Amgen INC. | $177.85 | 2022-2023 | Blincyto |
| Janssen Biotech, INC. | $156.84 | 2023 | Erleada |
| Incyte Corporation | $148.82 | 2022-2023 | Jakafi |
| Daiichi Sankyo INC. | $137.61 | 2023 | Enhertu, Injectafer |
| Eisai INC. | $121.54 | 2022-2023 | |
| Pfizer INC. | $104.26 | 2022-2024 | |
| Exelixis INC. | $99.99 | 2023 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $94.91 | 2022-2023 | |
| Seagen INC. | $89.83 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Jazz Pharmaceuticals INC. | $84.17 | 2023 | |
| Glaxosmithkline, LLC. | $73.73 | 2023 | Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $72.03 | 2023 | Qinlock |
| Blueprint Medicines Corporation | $53.02 | 2023 | Ayvakit |
| Amneal Pharmaceuticals LLC | $52.44 | 2023-2024 | Avastin |
| Genmab U.S., INC. | $50.81 | 2023 | Epkinly |
| Pharmaessentia USA Corporation | $49.38 | 2023 | Besremi |
| Puma Biotechnology, INC. | $48.88 | 2023 | Nerlynx |
| Sobi, INC | $47.14 | 2023 | |
| Mirati Therapeutics, INC. | $46.78 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $43.39 | 2022-2023 | Tavalisse, Rezlidhia |
| G1 Therapeutics, INC. | $43.33 | 2022-2023 | Cosela |
| Morphosys, US INC. | $41.55 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $38.97 | 2022-2023 | Imbruvica |
| Genentech USA, INC. | $38.88 | 2023-2024 | Avastin, Tecentriq |
| Secura Bio, INC. | $38.72 | 2023 | Copiktra |
| E.R. Squibb & Sons, L.L.C. | $28.63 | 2023 | Opdualag |
| Karyopharm Therapeutics INC. | $26.73 | 2023 | Xpovio |
| Beigene USA, INC. | $25.15 | 2023 | Brukinsa |
| Recordati_rare_diseases_inc. | $24.95 | 2023 | Sylvant |
| Ipsen Biopharmaceuticals, INC | $24.05 | 2023 | Tazverik |
| Sun Pharmaceutical Industries INC. | $23.63 | 2023 | Yonsa, Odomzo |
| Array Biopharma INC | $23.08 | 2023 | Mektovi, Braftovi |
| Eusa Pharma (US) LLC | $22.83 | 2022 | |
| Gilead Sciences, INC. | $22.64 | 2023 | |
| Stemline Therapeutics INC. | $21.98 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $21.81 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2023 | Ultomiris |
| Coherus Oncology, INC. | $19.74 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.66 | 2023 | Pylarify |
| Celgene Corporation | $19.19 | 2023 | Pomalyst |
| Organon LLC | $19.00 | 2023 | Ontruzant, Hadlima |
| Janssen Pharmaceuticals, INC | $17.33 | 2023 | Xarelto |
| Emd Serono, INC. | $17.28 | 2023 | Bavencio |
| Taiho Oncology, INC. | $13.28 | 2022 | |
| Immunogen, INC. | $13.19 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.